Additionally, while the study is ongoing, the preliminary results suggest that ADC combined with a PD-1 inhibitor is an effective neoadjuvant treatment for bladder cancer, with manageable safety profiles. This evidence concerns the gene PDCD1 and urinary bladder cancer.